Hui R, Özgüroğlu M, Daniel D, et al. Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract PL 02.02.
Tucatinib verlengt mediane overleving met 5,5 maand in finale analyse HER2CLIMB-studie
mrt 2022 | Borstkanker